gutflix
GI learning, personalised

Summary

USTEKINUMAB TREATMENT IN CROHN'S DISEASE AND ULCERATIVE COLITIS: A REAL-WORLD COMPARISON BETWEEN ITS EFFECTIVENESS AND SAFETY IN THIS TWO POPULATIONS

Gianluca Semprucci

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

In a real-world cohort of 131 bio-experienced IBD patients treated with ustekinumab, 52% achieved clinical response at week 52, with Crohn's disease patients showing higher rates of steroid-free clinical remission and endoscopic remission compared to ulcerative colitis patients.

KEY POINTS

- At week 52, 53% of CD patients and 50% of UC patients obtained clinical response; steroid-free clinical remission was achieved by 37.3% of CD patients versus 16.6% of UC patients.
- Endoscopic remission was reached by 29.5% of CD patients and 20% of UC patients; biochemical remission rates were comparable at 51.6% and 20% respectively.
- Among 131 patients (84 CD, 47 UC), nearly all were bio-experienced with prior anti-TNF therapy in 98% of CD and 83% of UC patients.
- Treatment persistence at 12 months was 84.5% in CD and 87.2% in UC; 15 adverse events occurred, with infections being the most frequent (9 of 15) and 4 classified as serious.
- The study provides real-world effectiveness and safety data relevant to clinicians managing bio-experienced moderate-to-severe IBD patients.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/13ae1870-743d-11ee-80f8-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.